Volume 63, Issue 5, Pages (May 2003)

Slides:



Advertisements
Similar presentations
Volume 76, Issue 9, Pages (November 2009)
Advertisements

Volume 62, Pages S12-S22 (December 2002)
Volume 66, Issue 1, Pages (July 2004)
Lipodermatosclerosis is Characterized by Elevated Expression and Activation of Matrix Metalloproteinases: Implications for Venous Ulcer Formation  Yared.
SiRNA Knockdown of Tissue Inhibitor of Metalloproteinase-1 in Keloid Fibroblasts Leads to Degradation of Collagen Type I  Masayo Aoki, Koichi Miyake,
Volume 61, Issue 2, Pages (February 2002)
Volume 78, Issue 3, Pages (August 2010)
Volume 76, Issue 9, Pages (November 2009)
Volume 57, Issue 1, Pages (January 2000)
Effects of suppressing intrarenal angiotensinogen on renal transforming growth factor- β1 expression in acute ureteral obstruction  Gyu-Tae Shin, Wook-Hwan.
Early aldosterone up-regulated genes: New pathways for renal disease?
Volume 69, Issue 4, Pages (February 2006)
Pressure distention compared with pharmacologic relaxation in vein grafting upregulates matrix metalloproteinase-2 and -9  Ada W.Y. Chung, PhD, Pooja.
Anders A. Tveita, Ole P. Rekvig, Svetlana N. Zykova 
Human renal epithelial cells produce the long pentraxin PTX3
Expression of Type XVI Collagen in Human Skin Fibroblasts: Enhanced Expression in Fibrotic Skin Diseases  Atsushi Akagi, Shingo Tajima, Yutaka Nagai 
Volume 62, Issue 4, Pages (October 2002)
Volume 54, Issue 6, Pages (January 1998)
Volume 68, Issue 6, Pages (December 2005)
Volume 60, Issue 5, Pages (November 2001)
Volume 63, Issue 4, Pages (April 2003)
Volume 63, Issue 6, Pages (June 2003)
Hiroshi Murakami, Lance Liotta, Robert A. Star  Kidney International 
Rat mesangial α-endosulfine
Preoperative treatment with doxycycline reduces aortic wall expression and activation of matrix metalloproteinases in patients with abdominal aortic aneurysms 
John Keeling, Guillermo A. Herrera  Kidney International 
Cytochrome P450 2E1 null mice provide novel protection against cisplatin-induced nephrotoxicity and apoptosis  Hua Liu, Radhakrishna Baliga  Kidney International 
Simvastatin suppresses tissue factor expression and increases fibrinolytic activity in tumor necrosis factor-α–activated human peritoneal mesothelial.
Volume 73, Issue 5, Pages (March 2008)
Volume 67, Issue 4, Pages (April 2005)
Volume 56, Issue 6, Pages (December 1999)
Volume 56, Issue 5, Pages (November 1999)
Membrane Type 1 Matrix Metalloproteinase Regulates Cellular Invasiveness and Survival in Cutaneous Epidermal Cells  Usha Nagavarapu, Kenneth Relloma,
Differential Expression of Matrix Metalloproteinases During Impaired Wound Healing of the Diabetes Mouse  Steven J. Wall, Dr, Damon Bevan, David W. Thomas,
Volume 65, Issue 6, Pages (June 2004)
Hiroyuki Yanagisawa, Nobuyuki Yamazaki, Gen Sato, Osamu Wada 
Oliver Vonend, Clare M. Turner  Kidney International 
1,25-dihydroxyvitamin D3 inhibits renal interstitial myofibroblast activation by inducing hepatocyte growth factor expression  Yingjian Li, Bradley C.
Gene transfer of truncated IκBα prevents tubulointerstitial injury
Erythropoietin stimulates proliferation of human renal carcinoma cells
Yukimasa Kohda, Hiroshi Murakami, Orson W. Moe, Robert A. Star 
Magnus Åbrink, Eric Larsson, Anders Gobl, Lars Hellman 
Volume 69, Issue 2, Pages (January 2006)
Volume 63, Issue 4, Pages (April 2003)
Volume 56, Issue 4, Pages (October 1999)
Volume 67, Issue 1, Pages (January 2005)
Volume 66, Issue 1, Pages (July 2004)
Volume 62, Issue 5, Pages (November 2002)
Volume 65, Issue 1, Pages (January 2004)
Yoshihisa Ishikawa, Masanori Kitamura  Kidney International 
Heat Shock-Induced Matrix Metalloproteinase (MMP)-1 and MMP-3 Are Mediated through ERK and JNK Activation and via an Autocrine Interleukin-6 Loop  Chi-Hyun.
Expression and Activation of Matrix Metalloproteinases in Wounds: Modulation by the Tripeptide–Copper Complex Glycyl-L-Histidyl-L-Lysine-Cu2+  Alain Siméon,
Effects of the Aminophenol Analogue p-Dodecylaminophenol on Mouse Skin
Reverse transcriptase-polymerase chain reaction study of anion exchanger-2 in canine tissues and different Madin-Darby canine kidney cell types  Graham.
Volume 64, Pages S21-S26 (October 2003)
Volume 61, Issue 6, Pages (June 2002)
Matrix Metalloproteinases of Epithelial Origin in Facial Sebum of Patients with Acne and their Regulation by Isotretinoin  Eleni Papakonstantinou, Alexios.
Volume 56, Issue 5, Pages (November 1999)
Volume 55, Issue 3, Pages (March 1999)
Volume 64, Issue 3, Pages (September 2003)
Laminin-8/9 is synthesized by rat glomerular mesangial cells and is required for PDGF- induced mesangial cell migration  Kim Hansen, Christine K. Abrass 
Volume 56, Issue 6, Pages (December 1999)
Volume 64, Issue 1, Pages (July 2003)
Production of hemopexin by TNF-α stimulated human mesangial cells
Wanfen Xiong, MD, PhD, Rebecca Knispel, BS, Jason Mactaggart, MD, B
J. Martin, T. Bowen, R. Steadman  Kidney International 
Volume 65, Issue 6, Pages (June 2004)
Effects of Hepatocyte Growth Factor on the Expression of Type I Collagen and Matrix Metalloproteinase-1 in Normal and Scleroderma Dermal Fibroblasts 
Volume 65, Issue 6, Pages (June 2004)
Matrix Metalloproteinase Inhibitor BB-3103 Unlike the Serine Proteinase Inhibitor Aprotinin Abrogates Epidermal Healing of Human Skin Wounds Ex Vivo1 
Presentation transcript:

Volume 63, Issue 5, Pages 1736-1748 (May 2003) Increased expression of MMP-2, MMP-9 (type IV collagenases/gelatinases), and MT1- MMP in canine X-linked Alport syndrome (XLAS)  Velidi H. Rao, George E. Lees, Clifford E. Kashtan, Ryochi Nemori, Rakesh K. Singh, Daniel T. Meehan, Kathyrn Rodgers, Brian R. Berridge, Gautam Bhattacharya, Dominic Cosgrove  Kidney International  Volume 63, Issue 5, Pages 1736-1748 (May 2003) DOI: 10.1046/j.1523-1755.2003.00939.x Copyright © 2003 International Society of Nephrology Terms and Conditions

Figure 1 General morphology of renal cortex from X-linked Alport syndrome (XLAS) dogs typical of those used in this study. Tissue was embedded in paraffin, cut at 3 μm, and stained using hematoxylin and eosin. Fibrosis scores, determined as described in the text, are indicated. C is normal. Kidney International 2003 63, 1736-1748DOI: (10.1046/j.1523-1755.2003.00939.x) Copyright © 2003 International Society of Nephrology Terms and Conditions

Figure 2 Immunofluorescence staining for matrix metalloproteinases (MMP-2 and MMP-9) and membrane type 1 MMP (MT1-MMP) in normal and X-linked Alport syndrome (XLAS) renal cortex. Cryosections from normal (A, B, and C) and XLAS (D, E, and F) dogs were subjected to immunofluorescence immunostaining using antibodies specific for the indicated MMP. Cryosections (G, H, and I) were reacted with preimmune serum as a control for background immunostaining. Bar is 100 μm. Kidney International 2003 63, 1736-1748DOI: (10.1046/j.1523-1755.2003.00939.x) Copyright © 2003 International Society of Nephrology Terms and Conditions

Figure 3 Western blot analysis of matrix metalloproteinases (MMP-2 and MMP-9) and membrane type 1 MMP (MT1-MMP) in normal and X-linked Alport syndrome (XLAS) tissue extracts. C is tissue extracts from unaffected; and A is from an XLAS dog with a fibrotic score of 3+. Results demonstrated that the antibodies used in the immunofluorescence studies are specific for the respective MMPs in dog tissues. Kidney International 2003 63, 1736-1748DOI: (10.1046/j.1523-1755.2003.00939.x) Copyright © 2003 International Society of Nephrology Terms and Conditions

Figure 4 Specificity of gelatin zymography for detecting matrix metalloproteinase (MMP) activity in tissue extracts. Lane 1, media from human fibrosarcoma cells (positive control); lane 2, tissue extract from unaffected; and lane 3 from an X-linked Alport syndrome (XLAS) dog with a fibrosis score of 3+. Both latent and active forms of MMP-2 and MMP-9 are denoted. Labels below the lanes indicate what was added to the gel incubation buffer, illustrating that the gelatinase activity is inhibited by ethylenediaminetetraacetic acid (EDTA), which is an inhibitor of MMPs, but not by phenylmethylsulfonyl fluoride (PMSF) or pepstatin A, demonstrating that activity is not due to serine or aspartate proteases. Kidney International 2003 63, 1736-1748DOI: (10.1046/j.1523-1755.2003.00939.x) Copyright © 2003 International Society of Nephrology Terms and Conditions

Figure 5 Interstitial disease in the X-linked Alport syndrome (XLAS) dogs is associated with markedly elevated matrix metalloproteinases (MMP-2 and MMP-9) activity. Sample numbers are reflecting animals described in Table 1. (A) Gelatin zymography for MMP-2 and MMP-9 proteolytic activity in necropsy tissue extracts from normal versus XLAS dogs. Quantitative analysis of MMPs. Gelatin zymograms were analyzed by scanning densitometry and expressed as arbitrary units to produce histograms. (B) The activity of total MMP-2 and MMP-9 are elevated in XLAS dogs compared to unaffected dogs. Total gelatinolytic activity represents the sum of both MMP-2 and MMP-9 activities. (C) Latent and active MMP-9 for individual samples are shown. (D) The values for total, MMP-2, and MMP-9 (both latent and active MMP-9 are shown) as mean and standard deviation for control and Alport dogs. The zymogram shown is representative of three independent experiments. *Statistical significance compared with control kidney extracts at P < 0.001. Kidney International 2003 63, 1736-1748DOI: (10.1046/j.1523-1755.2003.00939.x) Copyright © 2003 International Society of Nephrology Terms and Conditions

Figure 6 In situ gelatin zymography using gelatin films demonstrated strong gelatinolytic activity in the X-linked Alport syndrome (XLAS) dogs (Alport) as compared to control (Control). In this particular field, activity was in the interstitial space surrounding the glomerulus (G). The glomerulus itself, however, was negative for active metalloproteinase. The gelatinolytic activity is almost completely blocked in samples incubated on film containing 1,10-phenanthroline (Alport GI) indicating that the gelatinolytic activity is attributable to MMPs. Kidney International 2003 63, 1736-1748DOI: (10.1046/j.1523-1755.2003.00939.x) Copyright © 2003 International Society of Nephrology Terms and Conditions

Figure 7 Interstitial disease in X-linked Alport syndrome (XLAS) is associated with elevated matrix metalloproteinases (MMP-2 and MMP-9) mRNA transcripts. (A) Reverse transcription polymerase chain reaction (RT-PCR) from RNA isolated from normal and XLAS dog kidneys using primers specific for MMP-2, MMP-9, and glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Lanes 1 to 3, mRNA expression from normal unaffected dogs. Lanes 4 to 8, mRNA expression from XLAS dogs. GAPDH mRNA levels were also analyzed as a control for loading. (B) Semiquantification of mRNA transcripts for MMPs was performed using densitometry and normalized to GAPDH from the same sample. The results are presented as an index of mRNA expression (arbitrary units). Data are presented as the mean and standard deviation for three independent experiments. (C) The mean and standard deviation across groups of normal and Alport samples for three independent experiments. *Statistical significance compared with control samples (P < 0.001). Kidney International 2003 63, 1736-1748DOI: (10.1046/j.1523-1755.2003.00939.x) Copyright © 2003 International Society of Nephrology Terms and Conditions

Figure 8 Expression of membrane type 1 matrix metalloproteinase (MT1-MMP) mRNA transcripts in X-linked Alport syndrome (XLAS). (A) Shows reverse transcription polymerase chain reaction (RT-PCR) from RNA isolated from normal and XLAS dog kidneys using primers specific for MT1-MMP and glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Lanes 1 to 3, mRNA expression from normal unaffected dogs. Lanes 4 to 8, mRNA expression from XLAS dogs. (B) Semiquantification of mRNA transcripts for MT1-MMP was performed using densitometry and comparison to GAPDH as done in Figure 6. Data is presented as the mean and standard deviation for three independent experiments. (C) The mean and standard deviation across groups of normal and Alport samples for three independent experiments. *Statistical significance compared with control samples (P < 0.001). Kidney International 2003 63, 1736-1748DOI: (10.1046/j.1523-1755.2003.00939.x) Copyright © 2003 International Society of Nephrology Terms and Conditions